{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:41:53Z","timestamp":1771692113775,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":648,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Deutsche Krebshilfe (Bonn, Germany), Leuk\u00e4mie Liga e.V. (Duesseldorf, Germany), and Novartis"},{"name":"Amgen, Celgene, and Janssen-Cilag"},{"name":"Amgen and Celgene."},{"name":"Celgene and Janssen-Cilag"},{"name":"Novartis and Celgene"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.bbmt.2013.04.025","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T08:17:27Z","timestamp":1367482647000},"page":"1109-1115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma"],"prefix":"10.1016","volume":"19","author":[{"given":"Mark","family":"Korthals","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Sehnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Kronenwett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Strapatsas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Kobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Fenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.04.025_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.04.025_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-3-540-85772-3_10","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma","volume":"183","author":"Haas","year":"2011","journal-title":"Rec Res Cancer Res"},{"key":"10.1016\/j.bbmt.2013.04.025_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/10245330310001638965","article-title":"Molecular monitoring of minimal residual disease in patients with multiple myeloma","volume":"9","author":"Fenk","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.bbmt.2013.04.025_bib4","doi-asserted-by":"crossref","unstructured":"Szczepanski T, Orfao A, van der Velden, et\u00a0al. Minimal residual disease in leukaemia patients. Lancet Oncol 2001 Jul;2:409-417.","DOI":"10.1016\/S1470-2045(00)00418-6"},{"key":"10.1016\/j.bbmt.2013.04.025_bib5","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.025_bib6","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.04.025_bib7","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.04.025_bib8","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.04.025_bib9","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.bbmt.2012.05.009","article-title":"Minimal residual disease in myeloma: Are we there yet?","volume":"18","author":"Hart","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.025_bib10","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/leu.2009.268","article-title":"Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008","volume":"24","author":"Bruggemann","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.04.025_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/hon.860","article-title":"Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study","volume":"26","author":"Neumann","year":"2008","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bbmt.2013.04.025_bib12","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.025_bib13","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.025_bib14","first-page":"1365","article-title":"Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry","volume":"90","author":"Sarasquete","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.04.025_bib15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1365-2141.2004.05120.x","article-title":"Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma","volume":"126","author":"Bakkus","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.04.025_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbmt.2011.07.002","article-title":"The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter","volume":"18","author":"Korthals","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.025_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1600-0609.2010.01510.x","article-title":"Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma","volume":"85","author":"Putkonen","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2013.04.025_bib18","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.025_bib19","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/sj.leu.2400773","article-title":"Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement","volume":"11","author":"Billadeau","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.04.025_bib20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.bmt.1702628","article-title":"Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma","volume":"26","author":"Cremer","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.025_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bmt.1701767","article-title":"Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation","volume":"23","author":"Kiel","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.025_bib22","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.bmt.1703276","article-title":"Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation","volume":"28","author":"Lipinski","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.04.025_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/annonc\/mdi123","article-title":"Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma","volume":"16","author":"Raab","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2013.04.025_bib24","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1200\/JCO.1996.14.7.2167","article-title":"Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification\/ autotransplantation and who were conventionally treated","volume":"14","author":"Blade","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.04.025_bib25","first-page":"557","article-title":"Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma","volume":"89","author":"Fenk","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.04.025_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.04.025_bib27","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","article-title":"Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma","volume":"106","author":"Nowakowski","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.025_bib28","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2005-08-3398","article-title":"Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: A simple risk stratification system","volume":"107","author":"Dingli","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.025_bib29","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1080\/10428190701813018","article-title":"Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective study","volume":"49","author":"Liu","year":"2008","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2013.04.025_bib30","first-page":"317","article-title":"Use of quantitative ASO-PCR to predict relapse in multiple myeloma","volume":"105","author":"Cooke","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.04.025_bib31","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2002-06-1925","article-title":"Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells","volume":"101","author":"Rasmussen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.04.025_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.me.26.020175.001435","article-title":"Cellular kinetics staging, and immunoglobulin synthesis in multiple myeloma","volume":"26","author":"Durie","year":"1975","journal-title":"Annu Rev Med"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113001936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113001936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:45:37Z","timestamp":1761057937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113001936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S1083879113001936"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.04.025","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Monitoring of Minimal Residual Disease in the Peripheral Blood of Patients with Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}